2. Search Result
Search Result
Results for "

S+phase+arrest

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Peptides

16

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0316
    Mollugin
    2 Publications Verification

    		 JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
    Mollugin
  • HY-129440
    N-(p-Coumaroyl) Serotonin

    		NF-κB Toll-like Receptor (TLR) p38 MAPK NO Synthase COX ERK Caspase PDGFR MyD88 Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    N-(p-Coumaroyl) Serotonin is an orally active polyphenol found in safflower seeds with potent anti-inflammatory, antioxidant, and antitumor activities. N-(p-Coumaroyl) Serotonin suppresses NF‑κB, TLR4/MyD88 and MAPK signaling, activates NQO1/HO‑1 pathways, and inhibits pro‑inflammatory cytokines, iNOS and COX‑2 and ROS production. N-(p-Coumaroyl) Serotonin induces S‑phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injuries. N-(p-Coumaroyl) Serotonin acts as a vasodilator, regulates calcium dynamics. N-(p-Coumaroyl) Serotonin can be used for the research of neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure .
    N-(p-Coumaroyl) Serotonin
  • HY-N2217
    Rotundic acid

    		Akt mTOR p38 MAPK Apoptosis Phosphatase Interleukin Related NF-κB PI3K Keap1-Nrf2 Heme Oxygenase (HO) Toll-like Receptor (TLR) Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology Cancer
    Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
    Rotundic acid
  • HY-119979
    Cardanol monoene

    Cardanol C15:1

    		 Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism MMP CDK Caspase Bcl-2 Family PARP MDM-2/p53 Cholinesterase (ChE) Infection Inflammation/Immunology Cancer
    Cardanol monoene (Cardanol C15:1) is a phenolic compound which can be found in cashew nut shell liquid. Cardanol monoene can inhibit cancer cells proliferation, migration, cause S phase arrest, induce apoptosis, ROS production and mitochondrial depolarization. Cardanol monoene downregulates MMP-2, MMP-9, cyclinA1 expression, regulates CDK2, p53, Bax, cytochrome c, cleaved caspase-3, cleaved PARP, Apaf-1 expression and Bax/Bcl-2 ratio. Cardanol monoene shows weak DPPH radical scavenging activity and AChE inhibition activity. Cardanol monoene is lethal to Artemia salina nauplii. Cardanol monoene. Cardanol monoene can be used for the research of cancer, infection and inflamation .
    Cardanol monoene
  • HY-145963
    DRB18
    1 Publications Verification

    		 GLUT Cancer
    DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity .
    DRB18
  • HY-141512
    JB170
    3 Publications Verification

    		 PROTACs Aurora Kinase Cancer
    JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase .
    JB170
  • HY-N0670
    Tenacissoside H
    1 Publications Verification

    Tenacissimoside C

    		 PI3K Akt NF-κB Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Tenacissoside H (Tenacissimoside C) is a compound found in Caulis Marsdeniae Tenacissimae. Tenacissoside H shows anti-inflammation, anti-tumor and neuroprotective effects. Tenacissoside H inhibits PI3K/Akt and NF-κB signaling pathway. Tenacissoside H inhibits cancer cells proliferation, S phase arrest, and inhibits tumor growyh in mice. Tenacissoside H promotes neurological recovery of ischemia-reperfusion injury in mice by inhibiting inflammation and apoptosis. Tenacissoside H can be used for the research of cancer, inflammation and neurological diseases, such as esophageal cancer and cerebral ischemia .
    Tenacissoside H
  • HY-174346
    Skp2-IN-4

    		E1/E2/E3 Enzyme Apoptosis DNA/RNA Synthesis Cancer
    Skp2-IN-4 is an Skp2 inhibitor with a IC50 of 0.38  μM for Skp2-Cks1 binding. Skp2-IN-4 improves anti-tumor activity, inhibits the proliferation and induces S phase arrest by targeting Skp2. Skp2-IN-4 significantly enhances Cisplatin (HY-17394) chemosensitivity by suppressing the tumor cell stemness in NCl-H1299 xenograft mice model, promising for lung cancer and esophageal cancer research .
    Skp2-IN-4
  • HY-N3389
    Licoisoflavone A
    2 Publications Verification

    		 SARS-CoV Sirtuin CDK Apoptosis Infection Metabolic Disease Cancer
    Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC50 of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .
    Licoisoflavone A
  • HY-W097625
    6-Methoxyflavone

    		Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB Heme Oxygenase (HO) Neurological Disease Inflammation/Immunology Cancer
    6-Methoxyflavone is an orally active methoxyflavone. 6-Methoxyflavone suppresses neuroinflammation in microglia through the inhibition of TLR4/MyD88/p38 MAPK/NF-κB dependent pathways and the activation of HO-1/NQO-1 signaling. 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway in HeLa cells. 6-Methoxyflavone inhibits NFAT Translocation into the nucleus and suppresses T cell activation. 6-Methoxyflavone partially restores chronic ethanol-induced behavioral deficits in mice. 6-Methoxyflavone antagonizes chronic constriction injury and diabetes associated neuropathic nociception expression. 6-Methoxyflavone can be used for the study of cancer, inflammation and neurological diseases .
    6-Methoxyflavone
  • HY-112817
    8-Oxo-dGTP

    8-Oxo-Deoxyguanosine triphosphate

    		 Apoptosis Cardiovascular Disease Neurological Disease Cancer
    8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .
    8-Oxo-dGTP
  • HY-W016099
    3-Methyl-2-quinoxalinecarboxylic acid

    MQCA

    		 Drug Metabolite Cancer
    3-Methyl-2-quinoxalinecarboxylic acid (MQCA), an important N-oxide reductive metabolite of Quinocetone or Olaquindox, potently inhibits the growth of Chang liver cells through S phase arrest of the cell cycle .
    3-Methyl-2-quinoxalinecarboxylic acid
  • HY-111617
    BTR-1

    		Apoptosis Cancer
    BTR-1 is an active anti-cancer agent, causes S phase arrest, and affects DNA replication in leukemic cells. BTR-1 activates apoptosis and induces cell death .
    BTR-1
  • HY-W016099S
    3-Methyl-2-quinoxalinecarboxylic acid-d4

    MQCA-d4

    		 Isotope-Labeled Compounds Cancer
    3-Methyl-2-quinoxalinecarboxylic acid-d4 is the deuterium labeled 3-Methyl-2-quinoxalinecarboxylic acid. 3-Methyl-2-quinoxalinecarboxylic acid (MQCA), an important N-oxide reductive metabolite of Quinocetone or Olaquindox, potently inhibits the growth of Chang liver cells through S phase arrest of the cell cycle .
    3-Methyl-2-quinoxalinecarboxylic acid-d4
  • HY-103702
    TIP48/49-IN-1

    		Proton Pump DNA/RNA Synthesis Apoptosis Inflammation/Immunology Cancer
    TIP48/49-IN-1 is an orally active, specific RUVBL1/2 (TIP48/49) ATPase inhibitor with an IC50 of 59 nM against purified RUVBL1/2. TIP48/49-IN-1 inhibits the DNA replication process, leading to S-phase arrest. TIP48/49-IN-1 induces apoptosis. TIP48/49-IN-1 can be used for the research of non-small cell lung cancer (NSCLC) cells .
    TIP48/49-IN-1
  • HY-172915
    p53 Stabilizer 2

    		MDM-2/p53 DNA-PK Apoptosis Cancer
    p53 Stabilizer 2 is a 9'-cycloheptylselenomethyl-noscapine derivative and DNA-PKcs-dependent p53 stabilizer with low tubulin-binding affinity.p53 Stabilizer 2 induces S-phase arrest and apoptosis in cancer cells.p53 Stabilizer 2 can be used for the research of cancer .
    p53 Stabilizer 2
  • HY-129440R
    N-(p-Coumaroyl) Serotonin (Standard)

    		Reference Standards PDGFR ERK Caspase NF-κB Toll-like Receptor (TLR) p38 MAPK NO Synthase COX MyD88 Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    N-(p-Coumaroyl) Serotonin (Standard) is the analytical standard of N-(p-Coumaroyl) Serotonin (HY-129440). This product is intended for research and analytical applications. N-(p-Coumaroyl) Serotonin is an orally active polyphenol found in safflower seeds with potent anti-inflammatory, antioxidant, and antitumor activities. N-(p-Coumaroyl) Serotonin suppresses NF‑κB, TLR4/MyD88 and MAPK signaling, activates NQO1/HO‑1 pathways, and inhibits pro‑inflammatory cytokines, iNOS and COX‑2 and ROS production. N-(p-Coumaroyl) Serotonin induces S‑phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injuries. N-(p-Coumaroyl) Serotonin acts as a vasodilator, regulates calcium dynamics. N-(p-Coumaroyl) Serotonin can be used for the research of neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure .
    N-(p-Coumaroyl) Serotonin (Standard)
  • HY-150791
    FLDP-5

    		Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cancer
    FLDP-5 is a blood-brain barrier (BBB) penetrant curcuminoid analogues. FLDP-5 can induce production of ROS (Reactive Oxygen Species), DNA damage and cell cycle S phase arrest. FLDP-5 exhibits highly potent tumour-suppressive effects with anti-proliferative and anti-migratory activities on LN-18 cells .
    FLDP-5
  • HY-178940
    Apoptosis inducer 49

    		Apoptosis Checkpoint Kinase (Chk) CDK DNA/RNA Synthesis Bcl-2 Family Caspase Cancer
    Apoptosis inducer 49 is a selective apoptosis inducer with high specificity against CCRF-CEM leukemia cells (IC50 = 2.68 μM). Apoptosis inducer 49 enhances RNA synthesis and replication stress, activates the Chk1-p21 axis, leading to S-phase arrest. Apoptosis inducer 49 can inhibit Bcl-2 and activate caspase-3. Apoptosis inducer 49 can be used for the study of Leukemia .
    Apoptosis inducer 49
  • HY-175257
    Theophylline-platinum(IV) prodrug-1

    		PARP Reactive Oxygen Species (ROS) Apoptosis NF-κB ERK Bcl-2 Family TGF-β Receptor EGFR Cadherin Cancer
    Theophylline-platinum(IV) prodrug-1 is a PARP-1 inhibitor. Theophylline-platinum(IV) prodrug-1 enhances DNA damage, ROS production, mitochondrial dysfunction, apoptosis and S-phase arrest, along with reducing invasion and metastasis in cells. Theophylline-platinum(IV) prodrug-1 exhibits superior antitumor activity in the xenograft SKOV3-BRCA1-KD tumor model. Theophylline-platinum(IV) prodrug-1 can be used for the study of ovarian cancer .
    Theophylline-platinum(IV) prodrug-1
  • HY-179418
    Ceritinib-platinum(IV)-4-phenylbutyrate

    		Apoptosis Cancer
    Ceritinib-platinum(IV)-4-phenylbutyrate (complex 7) is a Ceritinib (HY-15656)-conjugated Platinum(IV) prodrug with anticancer activity. Ceritinib-platinum(IV)-4-phenylbutyrate induces S-phase arrest, DNA damage responses, and apoptosis. Ceritinib-platinum(IV)-4-phenylbutyrate combines cytotoxicity with immune and anti-invasive activation in cancer cell models. Ceritinib-platinum(IV)-4-phenylbutyrate can be used for cancer research, such as non-small cell lung cancer (NSCLC) .
    Ceritinib-platinum(IV)-4-phenylbutyrate
  • HY-177768
    HDAC-IN-96

    		HDAC Apoptosis Cancer
    HDAC-IN-96 (Compound 3f) is a selective HDAC1/2 inhibitor with IC50 values of 457.1 and 433.7 nM. HDAC-IN-96 has strong inhibitory activity against multiple hematological tumor cells (RS4;11, K562, RPMI-8226, U266), with IC50 values ranging from 2.11 to 5.35 μM. HDAC-IN-96 can induce cancer cells apoptosis and S phase arrest. HDAC-IN-96 can be used for the research of cancer, such as acute lymphoblastic leukemia .
    HDAC-IN-96
  • HY-N0316R
    Mollugin (Standard)

    		JAK Reference Standards NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
    Mollugin (Standard)
  • HY-175466
    BER-IN-1

    		PARP DNA/RNA Synthesis Apoptosis Cancer
    BER-IN-1 is a base excision repair (BER) inhibtor, targeting DNA abasic sites. BER-IN-1 cleaves abasic sites via β- and β,δ-elimination mechanisms, disrupts the base excision repair (BER) pathway and leads to DNA double-strand breaks (DSBs). BER-IN-1 can enhance the effectiveness of the PARP inhibitor Olaparib (HY-10162) in homologous recombination (HR)-proficient cancer cells (MDA-MB-231, HeLa, and SKOV3). BER-IN-1 induces an S-phase arrest and apoptosis companied with Olaparib (HY-10162). BER-IN-1 can be used for the research of cancer, such as breast, cervical and ovarian cancer .
    BER-IN-1
  • HY-175261
    DHI1

    		CDK Wee1 Checkpoint Kinase (Chk) Cancer
    DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC50 = 21.83 μM) and HL-60 (IC50 = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies .
    DHI1
  • HY-152135
    TJ08

    		Apoptosis Cancer
    TJ08, a 1,2,5-trisubstituted benzimidazole derivative, efficiently induces G1/S phase arrest and promotes apoptosis in various cancer cells. TJ08 is an anticancer agent .
    TJ08
  • HY-N10268
    3-Hydroxyterphenyllin

    NSC 299113

    		 Apoptosis Cancer
    3-Hydroxyterphenyllin is a metabolite of Aspergillus candidus.3-Hydroxyterphenyllin suppresses proliferation and causes cytotoxicity against A2780/CP70 and OVCAR-3 cells. 3-Hydroxyterphenyllin induces S phase arrest and apoptosis. 3-Hydroxyterphenyllin has the potential for the research of ovarian cancer .
    3-Hydroxyterphenyllin
  • HY-157323
    HDAC6-IN-28

    		HDAC Apoptosis Cancer
    HDAC6-IN-28 (compound 10C) is a potent inhibitor of HDAC6 with an IC50 of 261 nM. HDAC6-IN-28 significantly induces apoptosis and S-phase arrest in B16-F10 cells. HDAC6-IN-28 efficiently increases the expression of acetylated-α-tubulin in vitro and in vivo .
    HDAC6-IN-28
  • HY-146038
    Antitumor agent-55

    		Apoptosis ROS Kinase MDM-2/p53 Bcl-2 Family Cancer
    Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC50 of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3. Antitumor agent-55 induces G1/S phase arrest and apoptosis in PC3 .
    Antitumor agent-55
  • HY-146105
    Anticancer agent 65

    		Apoptosis MDM-2/p53 MMP Bcl-2 Family Reactive Oxygen Species (ROS) Cancer
    Anticancer agent 65 (compound 4c) shows excellent activity in cancer cell lines, especially A549 cells, with an IC50 of 1.07 μM. Anticancer agent 65 induces S-phase arrest in A549 cells and increases the expression level of p53 and p21. Anticancer agent 65 causes apoptosis, ROS generation and collapse of MMP in A549 cells .
    Anticancer agent 65
  • HY-176249
    Tetrazanbigen

    TNBG

    		 Apoptosis Cancer
    Tetrazanbigen is a potent and selective antitumor agent. Tetrazanbigen exhibits strong antitumor efficacy against six human cancer cell lines with an IC50 range of 2.13-8.01 μg/mL and an IC50 of 11.25 μg/mL against normal hepatocytes. Tetrazanbigen induces S phase arrest and apoptosis in QGY-7701 cells. Tetrazanbigen exerts its antitumor activity by inducing lipid accumulation accumulation in cancer cells .
    Tetrazanbigen
  • HY-N2217R
    Rotundic acid (Standard)

    		Reference Standards Akt mTOR p38 MAPK Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Rotundic acid (Standard) is the analytical standard of Rotundic acid (HY-N2217). This product is intended for research and analytical applications. Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
    Rotundic acid (Standard)
  • HY-178451
    NQO1-responsive prodrug

    		Apoptosis Cancer
    NQO1-responsive prodrug is a prodrug of Gemcitabine (dFdC) (HY-17026) with anti-cancer effect. NQO1-responsive prodrug remains stable in plasma and liver/intestinal S9 fractions, releasing dFdC in an NQO1-dependent manner. NQO1-responsive prodrug induces S-phase arrest and apoptosis. NQO1-responsive prodrug inhibits tumor growth in an A549 xenograft mouse model. NQO1-responsive prodrug can be used for breast and non-small cell lung cancer (NSCLC) research .
    NQO1-responsive prodrug
  • HY-173619
    EGFR-IN-160

    		EGFR Cancer
    EGFR-IN-160 (Compound R12) is an EGFR inhibitor (IC50 values are 1.62, 0.49 and 0.98 μM for EGFR WT, EGFR T790M and EGFR L858R/T790M/C797S, respectively). EGFR-IN-160 induces G2/M and S phase arrest and apoptosis in NCI-H522 cells, and has anticancer activity. EGFR-IN-160 has antioxidant effects against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM) .
    EGFR-IN-160
  • HY-164411
    KRC-00715

    		c-Met/HGFR Cancer
    KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models .
    KRC-00715
  • HY-175770
    mIDH1-IN-2

    		Isocitrate Dehydrogenase (IDH) PDK-1 Apoptosis Cancer
    mIDH1-IN-2 is a brain-penetrant isocitrate dehydrogenase 1 (IDH1) inhibitor. mIDH1-IN-2 shows subnanomolar potency against IDH1 R132H and R132C (IC50 = 80.0 and 58.0 nM) and minimal activity against wt-IDH1/2. mIDH1-IN-2 also inhibits PDK1 (IC50 = 0.61 μM) and reduces PDH phosphorylation dose-dependently. mIDH1-IN-2 can inhibit cells proliferation, induces S phase arrest and promotes apoptosis. mIDH1-IN-2 can be used for the research of cancer, such as glioma .
    mIDH1-IN-2
  • HY-147913
    PI3K/Akt/mTOR-IN-3

    		PI3K Akt mTOR Apoptosis Cancer
    PI3K/Akt/mTOR-IN-3 (compound 3d) is a potent PI3K/AKT/mTOR inhibitor. PI3K/Akt/mTOR-IN-3 displays the inhibitory activity in MCF-7, HeLa and HepG2 cells, with IC50 values of 0.77, 1.23, and 4.57μM, respectively. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 and HeLa cells at the concentration of 4 μM. PI3K/Akt/mTOR-IN-3 induces cell apoptosis and S phase arrest .
    PI3K/Akt/mTOR-IN-3
  • HY-181274
    Apoptosis inducer 59

    		Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism Cancer
    Apoptosis inducer 59, a camphorsulfonamide-based thiazolylhydrazone derivative, is a apoptosis inducer with antitumor activity. Apoptosis inducer 59 can inhibit cell migration and invasiveness, cause S phase arrest, induce ROS production and depolarise mitochondrial membrane potential. Apoptosis inducer 59 can be used for the research of cancer, such as breast cancer .
    Apoptosis inducer 59
  • HY-W016099R
    3-Methyl-2-quinoxalinecarboxylic acid (Standard)

    MQCA (Standard)

    		 Drug Metabolite Reference Standards Cancer
    3-Methyl-2-quinoxalinecarboxylic acid (Standard) is the analytical standard of 3-Methyl-2-quinoxalinecarboxylic acid. This product is intended for research and analytical applications. 3-Methyl-2-quinoxalinecarboxylic acid (MQCA), an important N-oxide reductive metabolite of Quinocetone or Olaquindox, potently inhibits the growth of Chang liver cells through S phase arrest of the cell cycle .
    3-Methyl-2-quinoxalinecarboxylic acid (Standard)
  • HY-181132
    dCASP1-55

    		PROTACs Caspase NF-κB Apoptosis Cancer
    dCASP1-55 is a cereblon-dependent caspase-1 (CASP1) PROTAC degrader. dCASP1-55 induces excessive NF-κB activation, apoptosis, and moderate S-phase arrest in leukemic cells. dCASP1-55 suppresses colony formation of leukemic cells. dCASP1-55 can be used for the research of cancer, such as myeloid malignancies and acute myeloid leukemia .
    dCASP1-55
  • HY-181694
    SeSA-HCPT

    		Topoisomerase HDAC Apoptosis Kinesin RAD51 Cancer
    SeSA-HCPT is an orally active dual-target inhibitor integrating Topo I and HDAC inhibition. SeSA-HCPT induces potent DNA damage, apoptosis, S-phase arrest in prostate cancer cells. SeSA-HCPT inhibits cancer cells proliferation and migration. SeSA-HCPT impairs homologous recombination by suppressing KIF4A-RAD51 signaling. SeSA-HCPT markedly inhibits CRPC tumor growth with minimal systemic toxicity .
    SeSA-HCPT
  • HY-182016
    PROTAC ATR degrader-3

    		PROTACs ATM/ATR Checkpoint Kinase (Chk) Apoptosis DNA/RNA Synthesis Caspase Bcl-2 Family MDM-2/p53 Cancer
    PROTAC ATR degrader-3 is a potent CRBN-based ATR PROTAC degrader with a DC50 of 127 nM. PROTAC ATR degrader-3 also degrades CHK1 with an DC50 of 135 nM. PROTAC ATR degrader-3 inhibits cancer cells proliferation, migration and invasion, triggers apoptosis and induces S phase arrest and DNA damage. PROTAC ATR degrader-3 achieves tumor growth inhibition in LoVo xenograft mouse model without apparent toxicity. PROTAC ATR degrader-3 can be used for the research of colorectal cancer .
    PROTAC ATR degrader-3
  • HY-181836
    IKKβ-IN-6

    		IKK Topoisomerase Apoptosis NF-κB Reactive Oxygen Species (ROS) Bcl-2 Family Cancer
    IKKβ-IN-6 is an antitumor agent. IKKβ-IN-6 inhibits IKKβ (IC50: 18.24 μM), thereby suppressing the phosphorylation of p65 and IκBα, blocking the nuclear translocation of p65, and subsequently regulating genes controlled by NF-κB. IKKβ-IN-6 also targets topoisomerase I (Topo I), induces DNA damage, ROS accumulation, loss of mitochondrial membrane potential, and S-phase arrest. IKKβ-IN-6 is applicable to related research on colorectal cancer .
    IKKβ-IN-6
  • HY-N17603
    Ginnalin A

    Acertannin

    		 Keap1-Nrf2 p62 Heme Oxygenase (HO) Cancer
    Ginnalin A (Acertannin) is a Nrf2 activator. Ginnalin A shows antiproliferative activity against HCT116, SW480 and SW620 cells with IC50 values of 24.8, 22.0, and 39.7 μM, respectively. Ginnalin A can induce cancer cells S phase arrest. Ginnalin A can activate the p62-Keap1-Nrf2 signaling pathway, significantly upregulate the mRNA and protein expression of Nrf2, HO-1, and NQO1, and promote the transport of Nrf2 from the cytoplasm to the nucleus. Ginnalin A can be used for the research of colon cancer .
    Ginnalin A
  • HY-180216
    USP1-IN-15

    		Deubiquitinase Cancer
    USP1-IN-15 is an orally active and selective USP1 inhibitor with an IC50 of 12.3 nM. USP1-IN-15 has a high specificity for USP1 with negligible inhibition against all off-target DUBs. USP1-IN-15 suppresses colony formation, induces S-phase arrest, and stabilizes ubiquitinated PCNA. USP1-IN-15 also shows synergistic antiproliferative activity. USP1-IN-15 achieves significant tumor growth inhibition in vivo. USP1-IN-15 can be used for BRCA-mutated breast cancer .
    USP1-IN-15
  • HY-132974
    Aminoflavone

    NSC-686288

    		 Aryl Hydrocarbon Receptor Reactive Oxygen Species (ROS) DNA Alkylator/Crosslinker DNA/RNA Synthesis Caspase Apoptosis HIF/HIF Prolyl-Hydroxylase Cancer
    Aminoflavone is an anti-tumor agent. Aminoflavone inhibits the expression of ITGA6/SOX2 by activating the AhR-miR-125b-2-3p axis, thereby targeting breast cancer stem cells. Aminoflavone induces an increase in intracellular ROS, increases the level of oxidative DNA damage marker 8-oxodG and DNA-protein cross-links. Aminoflavone causes S-phase arrest, activates caspase-3/8/9 and induces apoptosis (apoptosis). Aminoflavone inhibits HIF-1α expression in a manner independent of AhR. Aminoflavone can be used for the study of breast cancer .
    Aminoflavone
  • HY-183488
    R9-caPep

    RRRRRRRRRCCLGIPEQEY

    		 Apoptosis PARP Cancer
    R9-caPep (RRRRRRRRRCCLGIPEQEY) is a cell-penetrating peptide derived from proliferating cell nuclear antigen (PCNA). R9-caPep selectively blocks the interactions between PCNA and FEN1, as well as between PCNA and LIGI, while preserving the binding of POLD3 to PCNA. R9-caPep interferes with DNA synthesis and homologous recombination-mediated double-strand DNA break repair, inducing S-phase arrest, DNA damage accumulation, and apoptosis. R9-caPep inhibits the growth of tumor volume and weight of neuroblastoma in nude mice . R9-caPep can be used in research related to neuroblastoma and triple-negative breast cancer .
    R9-caPep
  • HY-180124
    CDK8-IN-20

    		CDK Wnt β-catenin c-Myc Reactive Oxygen Species (ROS) Cancer
    CDK8-IN-20 (Compound 67j) is a selective, potent and orally active type I CDK8 inhibitor with an IC50 of 70.5 nM. CDK8-IN-20 shows IC50 values of 147.8, 726.9 and 217.4 nM for homologous kinase CDK19, CDK7 and CDK9. CDK8-IN-20 can inhibit the Wnt/β-catenin pathway and downregulate the expression of β-catenin, Cyclin D1, and c-Myc. CDK8-IN-20 can induce ROS production and cause G2/M and S phase arrest. CDK8-IN-20can be used for the research of cancer, such as colon cancer .
    CDK8-IN-20
  • HY-181284
    BYBC-1

    		G-quadruplex DNA/RNA Synthesis Ras PI3K Akt ERK Caspase Apoptosis Cancer
    BYBC‑1 is a selective G4‑RNA‑targeting ligand with high affinity forKRAS and NRAS G4‑RNAs (Kd = 0.05-0.28 μM). BYBC‑1 stabilizes G4‑RNA structures in KRAS and NRAS mRNA, blocks thePI3K/AKT and MAPK/ERK pathways, activates the DNA damage response (DDR), suppresses energy metabolism, and induces S‑phase arrest and apoptosis. BYBC‑1 exhibits high selectivity over non‑malignant fibroblasts and significantly inhibits the growth of HCT‑116 xenograft tumors in vivo. BYBC‑1 can be used for the study of colorectal cancer .
    BYBC-1
  • HY-107272
    Chuanbeinone

    22-Epidelavinone

    		 Cholinesterase (ChE) Apoptosis Bcl-2 Family Caspase Interleukin Related TNF Receptor Toll-like Receptor (TLR) MyD88 NF-κB p38 MAPK Inflammation/Immunology Cancer
    Chuanbeinone (22-Epidelavinone) is an orally active alkaloid found in Fritillaria pallidiflora. Chuanbeinone shows cytotoxicity against mutiple cancer cells and can induces apoptosis and S phase arrest. Chuanbeinone downregulates Bcl-2, upregulates Bax, and activates caspase-3. Chuanbeinone exerts anti-inflammatory and antitussive effects by reducing pro-inflammatory cytokine (IL-1β, IL-6 and TNF-α) production and mRNA expression, and inhibiting TRIF-, MyD88-, NF-κB-, and MAPK-dependent signaling pathways. Chuanbeinone inhibits AChE and BChE with IC50 values of 7.7 and 0.7 μM. Chuanbeinone can be used for the researches of lung carcinoma, cough, inflammatory diseases .
    Chuanbeinone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: